USA TODAY US Edition

Are we prepared for the next coronaviru­s?

Scientists have a ‘road map’ for new vaccines

- Karen Weintraub

In some ways, we’ve been lucky with the COVID-19 pandemic.

The virus that causes it is highly contagious but not as lethal as others in its coronaviru­s family. The initial SARS virus killed roughly 1 in 10 of those infected; a relative called Middle East respirator­y syndrome, or MERS, still kills 1 in 3.

But we may not always be so lucky. With animals, including bats, colonized by hundreds of coronaviru­ses, another one might come along with the infectivit­y of SARS-CoV-2 and the death rate of MERS.

Hoping to prevent that, scientists on Tuesday unveiled a “road map” for developing a new vaccine that would be broadly protective against all coronaviru­ses.

If given ahead of time, such a vaccine could ideally avoid a future pandemic from this kind of virus, said Michael Osterholm, who directs the Center for Infectious Disease Research and Policy at the University of Minnesota, which is helping lead the effort.

“Can we achieve that? We don’t know,” he said. “We won’t know until we try.”

Need for new vaccines

The vaccines developed to fight COVID-19 “are remarkable” but have limits, said Dr. Bruce Gellin, chief of global public health strategy for The Rockefelle­r Foundation’s Pandemic Prevention Institute.

“We want to be more prepared and not chasing viruses (or variants) as they emerge,” he said.

The Rockefelle­r group and the Gates Foundation are partners in the initiative with Osterholm’s center, which has helped develop similar road maps for influenza, Ebola, Marburg, Lassa and Zika viruses.

By combining efforts, the three organizati­ons hope it will inspire others to join the effort and “compress the timeline” needed to develop next-generation safe, effective vaccines, Gellin said.

The U.S. government set aside $10 billion early in the pandemic to develop and purchase the current generation of vaccines. There has been no similar effort for the next generation.

“It’s all about time,” Gellin said. “How much can you do now that will shorten the time when you need it?”

What a future vaccine might look like

The plan lays out three possible visions for future vaccines.

First is a vaccine given as part of a routine childhood or adult vaccinatio­n programs that would protect against variants of the current SARS-CoV-2 virus, as well as other coronaviru­ses that may come along.

Second is the use of vaccines as part of a pandemic preparedne­ss strategy, making available vaccines that could protect against novel coronaviru­ses. These vaccines could be stockpiled to quickly interrupt transmissi­on and prevent an outbreak from turning into a global pandemic.

A third option might be a combinatio­n of the two, in which routine vaccinatio­ns could be provided to those at high risk for severe disease or exposure to a new virus, such as health care workers, with more vaccines in reserve in case of an outbreak.

All three would have to be affordable and usable in all parts of the world, including low-income countries; be able to prevent severe disease and, ideally, transmissi­on; protect against a wide range of coronaviru­ses; provide protection for at least a year; and be safe for everyone, including children, pregnant people and people who are immunocomp­romised.

What’s next?

Everyone wants to move on from the COVID-19 pandemic, but no one wants to ever be in this situation again. The goal of the road map, Gellin said, is “keep our guard when the appetite and resources for doing it are less than they were during the full-fledged emergency.”

While the map lays out the route, it doesn’t assign specific responsibi­lities, nor can it require anyone to take action, Osterholm said.

But at least it can help government, philanthro­pists and researcher­s understand what is happening and what needs to happen next, he said.

“Everybody has a fully transparen­t view of what needs to be done and what’s getting done – or what’s not getting done.”

 ?? STEPHANIE AMADOR/USA TODAY NETWORK ?? Lab manager Rita Smith processes blood samples as part of a Moderna COVID-19 vaccine trial at Vanderbilt University Medical Center in Nashville on Nov. 9, 2021.
STEPHANIE AMADOR/USA TODAY NETWORK Lab manager Rita Smith processes blood samples as part of a Moderna COVID-19 vaccine trial at Vanderbilt University Medical Center in Nashville on Nov. 9, 2021.

Newspapers in English

Newspapers from United States